• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Ultragenyx Pharmaceutical Inc. - Common Stock (NQ:RARE)

    22.86 -1.08 (-4.49%)
    Streaming Delayed Price Updated: 10:56 AM EDT, Jun 1, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 278,320
    Open 23.77
    Bid (Size) 22.83 (200)
    Ask (Size) 22.88 (500)
    Prev. Close 23.94
    Today's Range 22.86 - 24.05
    52wk Range 18.29 - 42.37
    Shares Outstanding 70,814,462
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    What to Know About This Fund's $5.4 Million Ultragenyx Purchase as Shares Slip 30% in One Year ↗
    Ultragenyx develops therapies for rare genetic diseases, with a portfolio spanning approved biologics and a pipeline of gene therapies. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire

    Performance

    YTD
    -3.1%
    -3.1%
    1 Month
    -7.7%
    -7.7%
    3 Month
    -0.7%
    -0.7%
    6 Month
    -31.5%
    -31.5%
    1 Year
    -36.7%
    -36.7%

    More News

    Read More
    News headline image
    Ultragenyx to Participate at Bank of America’s 2026 Healthcare Conference
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    Ultragenyx Pharma (NASDAQ:RARE) Dips After Q1 Miss as Pipeline Catalysts Loom ↗
    Via Chartmill
    News headline image
    Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    News headline image
    Ultragenyx to Host Conference Call for First Quarter 2026 Financial Results and Corporate Update
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    News headline image
    Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    News headline image
    ULTRAGENYX URGENT DEADLINE: Bragar Eagel & Squire, P.C. Reminds Ultragenyx (NASDAQ:RARE) Investors of the April 6th Lead Plaintiff Deadline and Urges Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    RARE FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026
    From Faruqi & Faruqi, LLP
    Via Business Wire
    News headline image
    RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    Ultragenyx 72 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - RARE
    From Kahn Swick & Foti, LLC
    Via Business Wire
    News headline image
    RARE Deadline: Rosen Law Firm Urges Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
    From The Rosen Law Firm, P.A.
    Via Business Wire
    News headline image
    ULTRAGENYX DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important April 6 Deadline in Securities Class Action – RARE
    From The Rosen Law Firm PA
    Via GlobeNewswire
    News headline image
    RARE SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026
    From Faruqi & Faruqi LLP
    Via GlobeNewswire
    News headline image
    Ultragenyx Vaults Toward Commercialization as FDA Accepts Landmark Gene Therapy BLA
    Via MarketMinute
    Topics Intellectual Property Lawsuit
    News headline image
    Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - RARE
    From SkyMedia, LLC
    Via GlobeNewswire
    News headline image
    RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    Ultragenyx Announces U.S. FDA Acceptance of BLA Resubmission for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    News headline image
    ULTRAGENYX PHARMACEUTICAL INC. (NASDAQ: RARE) CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Investors to Inquire About a Securities Fraud Class Action by April 6, 2026
    From Berger Montague
    Via GlobeNewswire
    News headline image
    Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
    From Kahn Swick & Foti, LLC
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadlines – RARE
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX016, a Sialic Acid Prodrug for the Treatment of GNE Myopathy
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    News headline image
    Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - RARE
    From SkyMedia, LLC
    Via GlobeNewswire
    News headline image
    Bragar Eagel & Squire, P.C. Reminds Ultragenyx (NASDAQ: RARE) Investors of the Upcoming April 6th Lead Plaintiff Deadline and Urges Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire

    Frequently Asked Questions

    Is Ultragenyx Pharmaceutical Inc. - Common Stock publicly traded?
    Yes, Ultragenyx Pharmaceutical Inc. - Common Stock is publicly traded.
    What exchange does Ultragenyx Pharmaceutical Inc. - Common Stock trade on?
    Ultragenyx Pharmaceutical Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Ultragenyx Pharmaceutical Inc. - Common Stock?
    The ticker symbol for Ultragenyx Pharmaceutical Inc. - Common Stock is RARE on the Nasdaq Stock Market
    What is the current price of Ultragenyx Pharmaceutical Inc. - Common Stock?
    The current price of Ultragenyx Pharmaceutical Inc. - Common Stock is 22.86
    When was Ultragenyx Pharmaceutical Inc. - Common Stock last traded?
    The last trade of Ultragenyx Pharmaceutical Inc. - Common Stock was at 06/01/26 10:56 AM ET
    What is the market capitalization of Ultragenyx Pharmaceutical Inc. - Common Stock?
    The market capitalization of Ultragenyx Pharmaceutical Inc. - Common Stock is 1.62B
    How many shares of Ultragenyx Pharmaceutical Inc. - Common Stock are outstanding?
    Ultragenyx Pharmaceutical Inc. - Common Stock has 2B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.